LLYのチャート
LLYの企業情報
| symbol | LLY |
|---|---|
| 会社名 | Lilly (Eli)_Co （LLY イ―ライリリ―） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 イーライ・リリー･アンド･カンパニー（Eli Lilly and Company）は製薬会社である。同社はヒト医薬品と動物用健康製品という2種類の製品の発見・開発・製造・販売を行う。ヒト医薬品事業は科学者によって発見または開発された医薬品の販売を行う。動物用健康製品事業は食用動物・コンパニオン動物向けの製品の開発、製造、販売を行う。同社のヒト医薬品は内分泌学製品、神経科学製品、腫瘍製品、免疫学製品、心臓血管製品を含む。動物用健康製品事業は食用動物とコンパニオン動物用製品を含む。 イ―ライ・リリ―は米国の製薬会社。主にヒトと動物用医薬品の開発・製造・販売に従事する。同社ヒト医薬品は糖尿病などの内分泌系、神経系、心臓血管系の疾患やがんに対する治療薬を含み、インスリン製剤「Humalog」が主力。動物用医薬品はエランコ・アニマル・ヘルスにおいて、牛・豚・鶏向けの抗生物質やペット用医薬品を扱う。本社所在地はインディアナポリス。 Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. It was founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today it remains true to that mission in all its work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. |
| 本社所在地 | Lilly Corporate Center Indianapolis IN 46285 USA |
| 代表者氏名 | David A. Ricks |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer |
| 電話番号 | +1 317-276-2000 |
| 設立年月日 | 1876年 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 38680人 |
| url | www.lilly.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | EBITDA（百万ドル） 7793.40000 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | 時価総額（百万ドル） 134407.90000 |
| 売上高 | 売上高（百万ドル） 24555.70000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 139092.40000 |
| 当期純利益 | 当期純利益（百万ドル） 3407.30000 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 31 December 2018 Eli Lilly And Co revenues increased 7% to $24.56B. Net income before extraordinary items increased 99% to $3.41B. Revenues reflect Human pharmaceutical products - Endocrinology segment increase of 16% to $11.7B Human pharmaceutical products-Immunology segment increase of 88% to $1.14B United States segment increase of 9% to $13.88B Europe segment increase of 7% to $4.23B. |
LLYのテクニカル分析
LLYのニュース
Eli Lilly (LLY) Q4 2022 Earnings Call Transcript 2023/02/03 01:00:20 The Motley Fool
LLY earnings call for the period ending December 31, 2022.
Eli Lilly touts skyrocketing Mounjaro prescriptions even as it reports an overall slump in 2022 revenue 2023/02/02 20:55:44 Endpoints News
Eli Lilly is betting big on its type 2 diabetes drug Mounjaro amid skyrocketing prescriptions since its launch. The company expects US net prices to continue to increase as access is broadened and paid prescriptions for the drug also increase. Prescriptions for Mounjaro peaked at about 180,000 per week in
Eli Lilly''s post-earnings decline is creating a buying opportunity for long-term investors 2023/02/02 19:43:52 CNBC
Club holding Eli Lilly''s (LLY) post-earnings sell-off is creating a buying opportunity Thursday. Our long-term conviction is not shaken.
Eli Lilly and Company (LLY) Q4 2022 Earnings Call Transcript 2023/02/02 19:25:14 Seeking Alpha
Eli Lilly and Company (NYSE:NYSE:LLY) Q4 2022 Earnings Conference Call February 2, 2023 10:00 AM ETCompany ParticipantsJoe Fletcher - Senior Vice President of Investor RelationsDave Ricks -…
Eli Lilly investors spooked by weak Mounjaro sales, but it''s the obesity drug approval that will unlock its value 2023/02/02 19:08:19 CNBC
Strong demand has stoked high hopes for Eli Lilly''s Mounjaro, but insurance companies are slow to get on board, sparking fears among investors.
This Top Pro Invests in Healthcare Trailblazers. 4 of Her Favorite Plays. 2022/12/01 07:30:00 Barron''s
Debra Netschert, co-manager of PGIM Health Sciences, looks for innovators in biopharma and healthcare delivery. Why Eli Lilly, UnitedHealth fit the bill.
FDA Pulls Emergency Use Authorization For Lilly''s COVID-19 Antibody Drug 2022/12/01 01:40:00 Finanz Nachrichten
INDIANAPOLIS (dpa-AFX) - The U.S. Food and Drug Administration has pulled its emergency-use authorization for bebtelovimab, a COVID-19 antibody co-developed by Eli Lilly & Co. (LLY) and AbCellera …
Setback for B.C.’s AbCellera as FDA pulls U.S. authorization for its COVID-19 antibody 2022/11/30 23:40:47 The Globe and Mail
Bebtelovimab, developed in partnership with Eli Lilly, got emergency okay for sale in February
Eli Lilly’s Alzheimer’s drug clears more amyloid early than Aduhelm in first-ever head-to-head. Will it matter? 2022/11/30 23:18:00 Endpoints News
Ahead of the FDA’s decision on Eli Lilly’s Alzheimer’s drug donanemab in February, the Big Pharma is dropping a first cut of data from one of the more interesting trials — but less important in a regulatory sense — at an Alzheimer’s conference in San Francisco. In the unblinded 148-person
Eli Lilly and Company (LLY) Management Presents at 5th Annual Evercore ISI HealthCONx Conference 2022 Conference Call Transcript 2022/11/30 22:01:05 Seeking Alpha
Eli Lilly and Company (NYSE:NYSE:LLY) 5th Annual Evercore ISI HealthCONx Conference 2022 Conference Call November 30, 2022, 12:10 PM ET Company Participants Jacob Van Naarden - Executive…
The Daily Biotech Pulse: Lilly Strikes Neurological R&D Collaboration, Valneva Confirms Vaccine Timelines, Biohaven Gains On Strong Migraine Drug Sales 2022/01/06 13:24:11 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Illumina Announces Co-Development Partnership With SomaScan For Accelerating Proteomics Illumina, Inc. (NASDAQ: ILMN ) announced it has entered into a definitive co-development agreement with SomaLogic to bring the SomaScan Proteomics Assay onto Illumina''s current and future high throughput next-generation sequencing platforms. This partnership accelerates the rapidly growing high throughput sector of the proteomics market. With the scale and speed of Illumina NGS technology, researchers can more effectively and efficiently make biological connections from genetic sequence to cellular function and accelerate opportunities for clinical impact, Illumina said. Lilly Announces R&D Collaboration With Entos To Develop Neurological Drug Eli Lilly and Company (NYSE: LLY ) said it has acquired exclusive rights to Entos Pharmaceuticals'' Fusogenix nucleic acid delivery technology to research, develop and commercialize nucleic acid products targeting the central and peripheral nervous system.
Lilly Buys Exclusive Rights Of Entos'' Fusogenix Nucleic Acid Technology 2022/01/06 12:36:56 Business Insider Markets
(RTTNews) - Pharma major Eli Lilly and Company (LLY), a pharmaceutical firm, and Entos Pharmaceuticals'' said in a joint statement on Thursday that Lilly has acquired exclusive rights of Entos'' Fusogenix nucleic acid delivery technology, for an initial payment of $50 million, which includes an equity investment by Lilly in Entos. In addition,
Here are 4 of Cramer''s top stock picks for 2022, including a red-hot oil giant 2022/01/05 18:39:56 CNBC
Appearing on CNBC''s "Halftime Report," Jim Cramer explained why Chevron, Eli Lilly, Honeywell and Bausch Health are some of his favorite stocks for the new year.
Here are 4 of Jim Cramer''s top stock picks for 2022 2022/01/05 18:39:56 CNBC
Appearing on CNBC''s "Halftime Report," Jim Cramer explained why Chevron, Eli Lilly, Honeywell and Bausch Health are some of his favorite stocks for the new year.
Peering Into Eli Lilly and Company''s Recent Short Interest 2022/01/05 18:01:49 Benzinga
Eli Lilly and Company''s (NYSE: LLY ) short percent of float has fallen 16.67% since last its last report. The company recently reported that it has 5.95 million shares sold short , which is 0.75% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.0 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of Full story available on Benzinga.com